AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10468801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (Neoral) at a dose of 2.5 mg/kg daily, increased to a maximum of 5 mg/kg daily for a maximum of 12 weeks, followed by either abrupt cessation or tapering off by 1 mg/kg weekly.
Number of subjects: 400
Study 10468801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (Neoral) treatment courses
Number of subjects: 400
Study 10468801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (Neoral) treatment
Number of subjects: 400
Study 10468801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (Neoral)
Number of subjects: 400
Study 8552462 — intervention group
Group type: EXPERIMENTAL
Intervention: Illuminated frame
Number of subjects: 0
Study 8552462 — intervention group
Group type: EXPERIMENTAL
Intervention: Frame added in an illuminated room
Number of subjects: 0
Study 2286467 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol 3 g single dose
Number of subjects: 158
Study 2286467 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 400 mg b.i.d. for seven days
Number of subjects: 158
Study 40485 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfadione (without surgery)
Number of subjects: 20
Study 40485 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfadione (during surgery)
Number of subjects: 20
Study 40485 — intervention group
Group type: COMPARATOR
Intervention: Enflurane (during surgery)
Number of subjects: 20
Study 31771803 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate and levodopa/carbidopa
Number of subjects: 101
Study 30359763 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 0
Study 30359763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30359763 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study 27658661 — intervention group
Group type: EXPERIMENTAL
Intervention: B&O suppository (15 mg/30 mg)
Number of subjects: 71
Study 27658661 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 71
Study 25785460 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 98
Study 23958473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day sphingomyelin (SM) for 14 days
Number of subjects: 10
Study 23958473 — intervention group
Group type: COMPARATOR
Intervention: Control diet without sphingomyelin
Number of subjects: 10
Study 21030684 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated albumin (GA) assay on fresh samples
Number of subjects: 180
Study 21030684 — intervention group
Group type: COMPARATOR
Intervention: Glycated albumin (GA) assay on stored samples
Number of subjects: 180
Study 19242031 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily IFA supplementation (100 mg elemental iron + 0.5 mg folic acid)
Number of subjects: 161
Study 19242031 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly IFA supplementation (100 mg elemental iron + 0.5 mg folic acid)
Number of subjects: 161
Study 19242031 — intervention group
Group type: COMPARATOR
Intervention: Once weekly IFA supplementation (100 mg elemental iron + 0.5 mg folic acid)
Number of subjects: 161
Study 19242031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IFA supplementation)
Number of subjects: 161
Study 17900401 — intervention group
Group type: COMPARATOR
Intervention: 10 mg bupivacaine 0.5% intrathecally plus 500 ml Ringer lactate solution (group B)
Number of subjects: 120
Study 17900401 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg bupivacaine 0.5% plus 25 mug fentanyl plus 500 ml Ringer lactate solution (group F)
Number of subjects: 120
Study 17900401 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg bupivacaine 0.5% plus 25 mug fentanyl intrathecally plus 500 ml Gelofusine intravenously (group G)
Number of subjects: 120
Study 17900401 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg bupivacaine 0.5% plus 25 mug fentanyl intrathecally plus 500 ml Gelofusine intravenously plus tight wrapping of the lower extremities with an Esmarch bandage (group E)
Number of subjects: 120
Study 15277930 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia (RA) - axillary brachial plexus block
Number of subjects: 100
Study 17108343 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa targeted to achieve a hemoglobin level of 13.5 g/dL
Number of subjects: 1432
Study 17108343 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa targeted to achieve a hemoglobin level of 11.3 g/dL
Number of subjects: 1432
Study 10888070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 10
Study 10888070 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (30 microg/kg)
Number of subjects: 10
Study 876794 — intervention group
Group type: EXPERIMENTAL
Intervention: Short incision (2.5 cm)
Number of subjects: 0
Study 876794 — intervention group
Group type: EXPERIMENTAL
Intervention: Long incision (4.5 cm)
Number of subjects: 0
Study 876794 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic release
Number of subjects: 0
Study 1761364 — intervention group
Group type: EXPERIMENTAL
Intervention: IMREG-1
Number of subjects: 49
Study 1761364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 6804114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized aerosol formulation of sodium cromoglycate (8 mg/day)
Number of subjects: 0
Study 6804114 — intervention group
Group type: COMPARATOR
Intervention: Standard sodium cromoglycate powder (80 mg/day)
Number of subjects: 0
Study 31818059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity elastic-band training
Number of subjects: 18
Study 31818059 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 18
Study 30192317 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 426
Study 29907780 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) prior to hand function training, 40 minutes before each session, twice a week for 8 weeks
Number of subjects: 12
Study 29907780 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) prior to hand function training
Number of subjects: 12
Study 29907780 — intervention group
Group type: COMPARATOR
Intervention: Sham Electrical Stimulation (Control)
Number of subjects: 12
Study 27153942 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 1515
Study 27153942 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducative Group Therapy (PeGT)
Number of subjects: 1515
Study 27153942 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Number of subjects: 1515
Study 27153942 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (CGI-s and SOFAS)
Number of subjects: 1515
Study 24776218 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid 10 mg/kg body weight
Number of subjects: 49
Study 24776218 — intervention group
Group type: COMPARATOR
Intervention: placebo saline 5 ml
Number of subjects: 49
Study 22703642 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Number of subjects: 80
Study 22703642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20104071 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 40
Study 20104071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17432704 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA (0.1 mmol/kg)
Number of subjects: 84
Study 17432704 — intervention group
Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 84
Study 15629610 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT plus TMZ (75 mg/m²/d) plus two cycles of TMZ (200 mg/m²/d for 5 days)
Number of subjects: 82
Study 15629610 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone (30 Gy)
Number of subjects: 82
Study 11966507 — intervention group
Group type: EXPERIMENTAL
Intervention: Irritable bowel syndrome (IBS)
Number of subjects: 288
Study 11966507 — intervention group
Group type: COMPARATOR
Intervention: Co-twin analyses of IBS
Number of subjects: 288
Study 10369195 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil in conjunction with oral steroids
Number of subjects: 0
Study 10369195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and oral steroids
Number of subjects: 0
Study 10369195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0
Study 10369195 — intervention group
Group type: COMPARATOR
Intervention: Oral high-dose corticosteroids
Number of subjects: 0
Study 10369195 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 0
Study 7759773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG) 400 mg/Kg every fourth week
Number of subjects: 0
Study 7759773 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir 800 mg twice a day for one week every month
Number of subjects: 0
Study 1969833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufotidine 600 mg bd
Number of subjects: 7
Study 1969833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30509370 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide-LAR
Number of subjects: 34
Study 30509370 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 29725755 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately heavy-load exercise (70% 1RM)
Number of subjects: 22
Study 29725755 — intervention group
Group type: COMPARATOR
Intervention: Low-load exercise with 80% arterial occlusion pressure (15/80)
Number of subjects: 22
Study 29725755 — intervention group
Group type: COMPARATOR
Intervention: Low-load exercise with 40% arterial occlusion pressure (15/40)
Number of subjects: 22
Study 29725755 — intervention group
Group type: COMPARATOR
Intervention: Low-load exercise with 0% arterial occlusion pressure (15/0)
Number of subjects: 22
Study 29725755 — intervention group
Group type: COMPARATOR
Intervention: Low-load exercise with 15% 1RM (15/0)
Number of subjects: 22
Study 25663177 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary catheter self-efficacy (C-SE) scale
Number of subjects: 202
Study 25663177 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary catheter self-management (C-SMG) scale
Number of subjects: 202
Study 24487666 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise combined with cognitive training (12 sessions, 3 times a week for 4 weeks, 75 min each session)
Number of subjects: 51
Study 24487666 — intervention group
Group type: COMPARATOR
Intervention: Mental relaxation training combined with cognitive training (12 sessions, 3 times a week for 4 weeks, 75 min each session)
Number of subjects: 51
Study 24487666 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise
Number of subjects: 51
Study 22176295 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte drink
Number of subjects: 9
Study 22176295 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 9
Study 20486419 — intervention group
Group type: EXPERIMENTAL
Intervention: Run-in periods in clinical trials
Number of subjects: 0
Study 18173142 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuwu Shengjing Decoction (LWD)
Number of subjects: 114
Study 18173142 — intervention group
Group type: COMPARATOR
Intervention: Wuzi Yanzong Pill (WYP)
Number of subjects: 114
Study 15886446 — intervention group
Group type: EXPERIMENTAL
Intervention: Masimo SET Rad-9 oximeter
Number of subjects: 9
Study 15886446 — intervention group
Group type: COMPARATOR
Intervention: Novametrix Oxypleth oximeter
Number of subjects: 9
Study 12072067 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil 2% (2 mL day-1) plus combined oral contraceptive
Number of subjects: 66
Study 12072067 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (52 mg day-1) plus ethinyl oestradiol (35 microg for 20 of every 28 days)
Number of subjects: 66
Study 9797104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (20 cigarettes per day for at least 2 years)
Number of subjects: 25
Study 10152782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin therapy
Number of subjects: 106
Study 10152782 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g q8h
Number of subjects: 106
Study 2677916 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative functional treatment with orthotic support
Number of subjects: 0
Study 2677916 — intervention group
Group type: COMPARATOR
Intervention: Operative functional treatment
Number of subjects: 0
Study 416763 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon hydrochloride (group A)
Number of subjects: 62
Study 416763 — intervention group
Group type: COMPARATOR
Intervention: Oxyphenonium bromomethylate (group B)
Number of subjects: 62
Study 31984480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 593
Study 31984480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 593
Study 31984480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study 31984480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 593
Study 31116262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) combined with music therapy (MT)
Number of subjects: 101
Study 31116262 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 101
Study 28270029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 67
Study 28270029 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group (no treatment)
Number of subjects: 67
Study 25874853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (2 × 20 mg)
Number of subjects: 18
Study 25874853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 25874853 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 18
Study 24238512 — intervention group
Group type: EXPERIMENTAL
Intervention: Famitinib (13-30 mg once daily)
Number of subjects: 24
Study 24238512 — intervention group
Group type: EXPERIMENTAL
Intervention: Famitinib (25 mg once daily)
Number of subjects: 24
Study 24238512 — intervention group
Group type: EXPERIMENTAL
Intervention: Famitinib
Number of subjects: 24
Study 22035131 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/losartan 50 mg
Number of subjects: 148
Study 22035131 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 148
Study 22035131 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/losartan 50 mg
Number of subjects: 148
Study 22035131 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 148
Study 17956153 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal aortic calcification scored on VFA images using a 24-point scale
Number of subjects: 816
Study 17956153 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal aortic calcification scored on VFA images using an 8-point scale
Number of subjects: 816
Study 15705666 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention consisting of four modules delivered by a trained facilitator using videotapes and interactive exercises.
Number of subjects: 101
Study 15705666 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 101
Study 12445221 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with higher RDA value
Number of subjects: 10
Study 12445221 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste with lower RDA value
Number of subjects: 10
Study 10350494 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation containing 5% flurbiprofen
Number of subjects: 0
Study 10350494 — intervention group
Group type: COMPARATOR
Intervention: Control formulation (0% flurbiprofen)
Number of subjects: 0
Study 7851558 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (CDDP 66 mg/m2 x 1, ADM 26 mg/m2 x 1, UFT 8 mg/kg/day for 6 months)
Number of subjects: 309
Study 7851558 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery only)
Number of subjects: 309
Study 7851558 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 309
Study 7851558 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (after adjusting for pN)
Number of subjects: 309
Study 1779485 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% UF-021, single instillation
Number of subjects: 0
Study 1779485 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% UF-021, twice daily for 4 weeks
Number of subjects: 0
Study 1779485 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% UF-021, single and long-term use
Number of subjects: 0
Study 7032532 — intervention group
Group type: EXPERIMENTAL
Intervention: Plafibride (N‐2‐(p‐chlorophenoxy)‐isobutyryl‐N'‐morpholinomethylurea, ITA 104)
Number of subjects: 0
Study 7032532 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 0
Study 31060476 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA Oolong tea
Number of subjects: 9
Study 31060476 — intervention group
Group type: EXPERIMENTAL
Intervention: High L-Theanine tea
Number of subjects: 9
Study 31060476 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea (low GABA)
Number of subjects: 9
Study 29653550 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g of Mecasin
Number of subjects: 36
Study 29653550 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g of Mecasin
Number of subjects: 36
Study 29653550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29653550 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with 100 mg of riluzole
Number of subjects: 36
Study 28199752 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcostal TAP block in combination with general anesthesia
Number of subjects: 49
Study 28199752 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 49
Study 26233509 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-40346527 100 mg
Number of subjects: 95
Study 26233509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 24142206 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (3 once-weekly doses of 50 mg) co-administered with warfarin (30 mg)
Number of subjects: 13
Study 24142206 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (30 mg) alone
Number of subjects: 13
Study 21134325 — intervention group
Group type: COMPARATOR
Intervention: Calcium HMB (CaHMB) - gelatin capsule, 1 g
Number of subjects: 8
Study 21134325 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB free acid gel swallowed (FASW)
Number of subjects: 8
Study 21134325 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB free acid gel held sublingual for 15 s then swallowed (FASL)
Number of subjects: 8
Study 18211121 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 200 mg twice daily
Number of subjects: 63
Study 18211121 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 400 mg twice daily
Number of subjects: 63
Study 18211121 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 600 mg twice daily
Number of subjects: 63
Study 18211121 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 800 mg twice daily
Number of subjects: 63
Study 18211121 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 800 mg once daily
Number of subjects: 63
Study 18211121 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine 1200 mg once daily
Number of subjects: 63
Study 18211121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16629939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cernevit (vitamin preparation with glycocholic acid)
Number of subjects: 74
Study 16629939 — intervention group
Group type: COMPARATOR
Intervention: Control vitamin supplements
Number of subjects: 74
Study 15323062 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg)/Indapamide (0.625 mg)
Number of subjects: 214
Study 15323062 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 214
Study 11260239 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer 1 (lipid-rich)
Number of subjects: 36
Study 11260239 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer 2 (lipid-rich)
Number of subjects: 36
Study 11260239 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer 3 (lipid-rich)
Number of subjects: 36
Study 11260239 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer 4 (less lipid-rich)
Number of subjects: 36
Study 11260239 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer 5 (less lipid-rich)
Number of subjects: 36
Study 11260239 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer 6 (less lipid-rich)
Number of subjects: 36
Study 11260239 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 36
Study 9032174 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids and related compounds in bronchoalveolar lavage (BAL) fluid
Number of subjects: 0
Study 9032174 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 0
Study 8500246 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 1446
Study 8500246 — intervention group
Group type: COMPARATOR
Intervention: No warfarin treatment
Number of subjects: 1446
Study 8500246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients experiencing thromboembolic events
Number of subjects: 1446
Study 3548616 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin at midnight before the operation
Number of subjects: 36
Study 3548616 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin and 75 mg of dipyridamole at midnight and an additional 75 mg of dipyridamole at 6 AM
Number of subjects: 36
Study 3548616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 29241713 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial heating (hot packs) applied for 30 minutes
Number of subjects: 21